$DLYT: look for BIG BOUNCE-- DD PACK HERE>>>> 19 patents

New Post Public Reply Private Reply Replies (0) Message Board
SHEEPWOLF
620
$DLYT: look for BIG BOUNCE-- DD PACK HERE>>>> 19 patents !!!
CREDIT: Mr.Clean

ATTENTION: MR CLEAN’S ULTIMATE DD PACKAGE

$$DLYT$$



Benjamin Franklin once said, “To succeed, jump as quickly at opportunities, as you do at conclusions.” Recently, we were blessed with an opportunity that would make drawing those conclusions a lot easier.

If you have been in the public squalor, they call the “OTC” for any amount of time, you know that it can be a nightmare and a wet dream in the same sleep cycle. Ups, downs, grins, frowns, highs, lows, ebbs flows, and a symbiotic relationship with disorientation only begins to summarize it. The chances of finding something before the rest of the market is about as rare as AOC creating jobs. It just doesn’t happen. Everyone reading this has found this stock in one way or another, and if you own shares, I want you to take a few minutes and thank your God. Whomever that may be. Jesus, Buddha, Zeus, John Stamos, I don’t care who it is just thank someone. Here’s why;

We will start with the OS. We all love low floaters and DLYT has a perfect shares structure. Not bloated and not too thin. This offers liquidity at higher levels, but also doesn’t require massive dollar volume to move it to those levels.

REVENUE GROWTH

Key financial performance from operations for the fourth quarter and 2018 year-end include:

Net revenue for the quarter ended December 31, 2018 was $465,415, versus $133,848 for the same period in 2017 (approximately 250% more).

Net revenue for the year ended December 31, 2018 was $1,381,251 compared to $382,934 in 2017 (factor of 3.6 more).

Gross Margin for the quarter ended December 31, 2018 was $151,184 versus $29,077 for the same period in 2017 (approximately 420% more).

Gross Margin for the year ended December 31, 2018 was $459,857 compared to $70,387 in 2017 (factor of 6.5 more).

Operating expenses for the quarter ended December 31, 2018 was $425,923, down from $1,054,941 during the same period in 2017 (a reduction of approximately 60%).

Expenses for the year ended December 31, 2018 were $2,115,448, compared to $2,525,499 for 2017 (a reduction of approximately 16%).

Loss from operations for the quarter ended December 31, 2018 was $274,779, versus $1,025,864 for the same period in 2017 (a reduction of approximately 73%).

Loss from operations for the year ended December 31, 2018 was $1,655,631, compared to $2,455,112 for 2017 (a reduction of approximately 32%).

IMPORTANT- Not only did DLYT increase its revenues by 360% YOY but they also REDUCED their cost of sales and DECREASED their loss from operations significantly.

Dais has been around for 20+ years so we are not investing in some no product start-up here. This company holds 19 patents already!

https://patents.justia.com/search?q=dais+analytics

Not only do they hold 19 patents, but these patents are highly valuable and desirable. Proof of this can be found in the most recent lawsuit between DLYT and SOEX. SOEX is one of DLYT’s partners in China. They also hold a 16% stake in DLYT. Apparently, SOEX had a mole working for Dais for 10 years. When he headed back to China, he tried to steal the patented tech. Dais caught wind of this and sued SOEX. After a year of arbitration something strange happened only a few days ago. On august 9th 2019, Dais DISMISSED the case with prejudice. Why? After all, Dais was full steam ahead on getting what they were owed, shown here from the most recent 10Q;

Pursuant to the Distribution Agreement, Soex is in material breach of the following:

(1)

Section 1(a) of the Distribution Agreement for Soex's failure to make a $225,000 payment to the Company for the appointment of Soex as the exclusive distributor of the Products in the Field and Territory (the "Distribution Payment Default" in accordance with the terms set forth in the Distribution Agreement. Such payment was due on October 20, 2014 (the "Payment Date" .

(2)

Section 8(b) of the Distribution Agreement for Soex's failure to make a $225,000 payment to the Company for the grant of the license and right to manufacture, sell, lease and distribute Products (excluding manufacture of MTM), and to use the Intellectual Property in connection therewith (the "License Payment Default" and, together with the Distribution Payment Default, the "Payment Default" in accordance with the terms set forth in the Distribution Agreement. Such payment was due on the Payment Date.

(3)

Section 15(b) of the Distribution Agreement for Soex's failure to issue to the Company 25% of the equity (the "Equity Default" of SOEX (Beijing) Environmental Protection Technology Company Limited (the "China Subsidiary" .

As a result of the above, we terminated the Soex Distribution Agreement. As provided in Section 14(e) of the Soex Distribution Agreement, the Company has the right to enforce any obligation due to us by Soex. As a result, Soex still must (a) pay the remaining $450,000 due under the Distribution Agreement and the amount of Royalties due, plus interest at 1.5% per month (18% per year) with interest accruing from the date that payment was due and (b) issue to us 25% of the equity of SOEX (Beijing) Environmental Protection Technology Company Limited. As provided in Section 14(b), neither us nor Soex shall be liable for compensation, reimbursement or damages due to loss of profits on sales or anticipated sales or losses due to expenditures, investments or commitments made or in connection with the establishment, development or maintenance of the business.

On October 24, 2018, the Company initiated a third lawsuit against an affiliate of Soex, Zhongshan Trans-Tech New Material Technology Co. Ltd. Zhongshan, China, (“Transtech”), and the Chairperson of the affiliate and Soex, based on new information learned by the Company. The Company will seek maximum relief and damages for this on-gong and growing illegal misuse the Company’s Intellectual Property. The Company feels this third action will lead in a judgment in favor of the Company.

With this knowledge we must ask ourselves, why did Dais dismiss the case?

I believe I found the answer further down the statements.

“The company is holding Preliminary discussions with parties who are interested in licensing, PURCHASING THE RIGHTS TO or establishing a joint venture to commercialize applications of the company’s technology.”

Could this be SOEX? I truly believe that Dais was either offered a buyout for one of their patents or was promised a better deal from SOEX.

We should get a better picture of this in the next 10Q, just a few days away.

Next up, we have a huge licensing deal with HAIER group. Maybe you’ve heard of them. They are a 65b dollar company in China. Haier is using Dais patented tech in their refrigerators. This deal is worth a whopping 73 Million dollars ANNUALLY. The revenues haven’t even been realized on the books yet. Here is an Excerpt from the financials;

“In the quarter ending September 30, 2018, the Company (September 2018) announced that we entered into a second definitive two-part, license agreement with the Haier Group of Qingdao, China for a new product for Haier’s HVAC cooling systems. The new product is anticipated to have a significant revenue impact for Dais, projected to be $73 million or more annually when successfully field tested and fully deployed. Revenues for Dais could begin as early as the last quarter of 2019. The product is an innovative PolyCool™ condensing unit being incorporated into a commercial Haier cooling line that is planned to be deployed into Haier’s Greater China sales and distribution channels. The product is moving into field testing with deployment into Haier’s sales channels throughout Greater China.”

Paying attention yet? Want to know more? Here’s an interview from the CEO of Dais where he mentions the HAIER deal and its capacity.

CEO Tim Tangredi of Dais Analytic Corporation (OTCQB: DLYT) Feb '19


https://youtu.be/kFXxa4UIHtM


If you listened to the whole interview, you would have caught Tangredi mentioning his chat with President Xi of China. At first, I thought this was BS, but I dug a little further and found this little nugget.

https://www.cnbc.com/2017/11/02/here-are-the-...trump.html

Does #9 sound familiar????

Tim Tangredi, CEO of DLYT accompanied PRESIDENT TRUMP in China!

“A priority of Trump’s Asia tour will be bolstering trade with some of the United States’ top business partners.”

ARE YOU LISTENING YET????

Just like any other company, Dais has some debt. Unlike most Pink sheet companies, the debt isn’t significant. There was a note from February 2019 for $155,000. Nothing crazy. There are also some lingering notes from 2018 that are due to mature on August 15th. These notes were extended from March 2019. I believe the reason for the extension was because August 15th is the due date for Q2 financials. The note holders knew that Q2 would be strong. Moving forward we may have pockets of light dilution, but again, nothing overwhelming. In fact, the notes could turn out to be extended further. 1.3m in debt is simply nothing for a company that is increasing revenues rapidly. No loan sharks or toxic convertibles that convert at .0000005. Here are the notes in detail;

February 2019 Note

On February 20, 2019, the Company issued a convertible note with a face amount of $155,000. The note and related accrued interest are convertible, at the option of the holder, into shares of the Company’s common stock at a conversion price of 60% of the lowest trading price for 15 days prior to conversion. The note bears interest at 8% per year and matures on February 20, 2019. The note contains original issue discount aggregating $12,500 which is being amortized over the life of the note. The Company has also agreed to issue 1,000,000 shares of common stock with a value of $10,000 in connection with the note. The shares (which have not been issued at March 31, 2019) have been valued at $10,000. This cost will also be amortized over the life of the note. The Company received cash proceeds of $142,500.

2018 Notes

The company entered various convertible notes during 2018, aggregating $1,254,250. The notes all mature during 2019. During the three months ended March 31, 2019, three notes that came due during the period were extended to August 15, 2019. Pursuant to the terms of the extensions, we have agreed to issue one million shares of common stock for each month that the notes are outstanding, commencing in April 2019.

On a lighter note, Dais has drawn the attention of the U.S. Government more than once.

Dais Analytic Receives $1.2 Million From U.S. Department of Energy to Advance NanoAir Membrane HVAC Technology

Award Supports Dais' Drive to Commercialize a Product Line with the Potential to Change the Architecture of a 100+ Year Old Industry, Improving Efficiency and Reducing Its Carbon Footprint

ODESSA, FL--(Marketwired - May 12, 2015) - Dais Analytic Corporation (OTCQB: DLYT), a commercial nanotechnology materials business selling its industry-changing technology into the worldwide energy and water markets, today announced it has been selected to receive additional funding of $1.2 million from the U.S Department of Energy (DOE) to further commercialize its Heating, Ventilation, and Air-Conditioning (HVAC) membrane technology for its NanoAir™ product. The award is part of a total investment of nearly $8 million announced at the end of April by the Energy Department to advance research and development of next-generation heating, ventilating, and air conditioning (HVAC) technologies.

Even the department of defense has invested 8 million into Dais. They still receive money from the grant today, as reflected in the financial statements.


In conclusion, I would like to express that some of the statements in this article are opinion based. I am not a financial advisor, and shares should not be purchased on my recommendation. However, with that being said, I believe DLYT has an incredible outlook moving forward. They have grabbed attention from some of the biggest names in the industry, who all seem to want a piece of Dais technology. What if Haier decided to buy us out? 250m dollar buyout here sells us at 80 cents. Not a crazy evaluation for a company they already have a multi-year, 73m dollar agreement with. Although this may be speculation, it makes sense. With the HAIER deal ramping up and set to hit the books in a few months, I wouldn’t venture far to say that Dais is a major buyout candidate. Their books aren’t dirty, and they have extremely valuable patents. Patents so valuable that Chinese companies have even tried to steal it. Mix those in with rapid revenue growth, increased distribution channels through licensing partnerships, and the growing interest in clean air products, and you are left with the aforementioned “opportunity.” The question is, will you jump at it?
Sojourner here following God, obeying God, and cleaving to Him. The journey is onward.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ad Council Expands Board, Taps Meta Exec as Vice Chair

Updated Category News Views 203

An Unexpected Shuffle at the Ad Council Alright, folks, let's talk shop about the recent shake-up in the nonprofit realm. The Ad Council, which has been around longer than some of the giants controlling today's marketing landscapes, just plumped up its Board of Directors with 23 new heavy-hitters. We're talking about leaders from every nook and cranny of the...

Continue Reading
Georgia-Pacific's $150M Bet on Bathroom Tissue Future

Updated Category News Views 0

Georgia-Pacific is throwing down a cool $150 million to jazz up its mill in Palatka, Florida. Yep, they're not just scrubbing the edges, but rebuilding one of the paper machines there—from the ground up. Why the fuss? Well, in the paper game, keeping your machines ahead of the pack means everything. In this case, it’s about ramping up for dear ol’ Angel Soft® bath...

Continue Reading
Nektar Therapeutics Gears Up for Q3 Financial Reveal

Updated Category News Views 56

Anticipation Builds as Nektar Preps Financial Report Ah, the life of a biotech investor, riding high or gripping the rail as tides turn with every quarterly report. This time, we're turning our gaze to Nektar Therapeutics and their Q3 financial results slated for release on November 12th, just as the market dust starts settling for the day. Now, if you’re wired to...

Continue Reading
Custom Homes Shine: Florida’s Lucrative Property Move

Updated Category News Views 0

Why Custom Homes Are Worth the Investment in Florida Ever thought about sinking some cash into Florida's real estate game? Well, building a custom home might just be your golden ticket, according to Paul H Schaefer II from Sage Homes LLC. I mean, everyone knows Florida's housing market is as spicy as a chili pepper, but custom homes seem to be the secret sauce here....

Continue Reading
Firmable Climbs G2 Ranks in Sales Intelligence

Updated Category News Views 53

Success stories aren't written overnight, and Firmable's recent leap in G2's rankings proves that point. This AI-native B2B sales powerhouse has muscled its way from #8 to #4 on the global Momentum Grid for Sales Intelligence, marking a dramatic rise that's hard to ignore. Being recognized at this level shows the company's on a solid path, but let's see what makes this...

Continue Reading
Webull Faces Class Action: Deadline Looms Dec 2026

Updated Category News Views 60

Sinking Shares: The Webull Saga Unfolds Shady business practices can really make a stock take a nosedive, and that's what's happening with Webull Corporation, trading under NASDAQ:BULL. The alarm bells started ringing when the truth about their operations and ties to China came out. Turns out, what looked like a stable American fintech platform had its roots digging deep...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 15

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
Software Updates Costly: UX Not the Biggest Culprit

Updated Category News Views 68

Breaking Updates Trump UX Changes Here's the real scoop: software updates that break functionality are setting companies back more than those user experience (UX) tweaks that folks gripe about but usually muddle through. According to a recent LITSLINK study, even three figures that supposedly quantify UX losses turn out to be questionable at best. Real-world Disasters:...

Continue Reading
LabWare Loop: A Game Changer for Lab Data Integrity

Updated Category News Views 58

Breaking Down Silos in Lab Environments When it comes to the controlled chaos of laboratory operations, data integrity is the name of the game. We're talking about a new way of doing things that doesn't demand a physics degree just to connect the dots between gizmos and databases. Enter LabWare Loop, a solution that's rewriting the data playbook by linking multi-vendor...

Continue Reading
SELCO and Numerica Unite: A Merger That's All Heart

Updated Category News Views 47

Big Merger in Credit Union World: SELCO and Numerica Sometimes, it ain't all about dollars and cents. That's the vibe I'm picking up from this merger of equals between SELCO Community and Numerica Credit Unions. This isn't a Wall Street hustle, it's hometown hustle—where the biggest reward isn't just a fat line at the bottom but seeing your community thrive. The Vision...

Continue Reading

Top 5 Most Recently Viewed Articles

Lucid Diagnostics Partners with LEAA Health for EsoGuard Testing

Updated Category News Views 227

Lucid Diagnostics Partners with LEAA Health for EsoGuard Testing LEAA Health's membership-based patients can now access the innovative EsoGuard esophageal precancer testing as part of their enhanced personalized care services. This collaboration marks a significant milestone for Lucid Diagnostics Inc. (Nasdaq: LUCD), a leader in cancer prevention medical diagnostics....

Continue Reading
Exploring the Growth of the Silicone Market Towards 2030

Updated Category News Views 234

Understanding the Silicone Market Dynamics The silicone market is on a significant growth trajectory, poised to reach approximately USD 33,246.3 million by 2030, with a robust compound annual growth rate (CAGR) of 5.2%. This forecast highlights the dynamics driving market expansion, making it essential for industries to adapt and embrace silicone’s diverse applications....

Continue Reading
CAPREIT Reveals Monthly Distribution for Investors

Updated Category News Views 89

CAPREIT Announces Monthly Distribution for September 2024 CAPREIT, a leading real estate investment trust in Canada, has announced a distribution of $0.125 per Unit for September 2024. This significant declaration reflects their dedication to delivering steady returns for investors. In total, this represents an annualized distribution of $1.50 per Unit. Unitholders should...

Continue Reading
Invivyd Engages Investors at Healthcare Innovation Conference

Updated Category News Views 56

Invivyd to Showcase Innovations at Healthcare Conference Invivyd, Inc. (Nasdaq: IVVD), a dedicated biopharmaceutical company focused on combating serious viral infections, has announced its participation in an upcoming prominent event, the Guggenheim Securities Healthcare Innovation Conference. This event takes place from November 11-13, offering a unique opportunity for...

Continue Reading
Athena Security Introduces Innovative Telepresence Technology

Updated Category News Views 183

Revolutionizing Security with Innovative Technologies Athena Security is making waves in the world of security technology with the introduction of its groundbreaking innovations. The newly developed Telepresence Officer stands as a significant advancement, working as a workforce multiplier. This technology is designed to meet soaring security demands in critical...

Continue Reading